In the opinion of some lawyers, according to an article at Bloomberg, the verdict in the New Jersey Vioxx trial may depend on the closing arguments, which begin today. An except:
“The summations are critical because the science in this case is somewhat hazy,” said attorney Samuel Davis of Davis, Saperstein & Salomon, who attended daily and filed 94 Vioxx suits against Merck. “The winning side is going to be the one that can simplify what has been a rather complex and detailed explanation of what caused Mr. Humeston’s heart attack.”
